Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that ...

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that the ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Novo Nordisk's popular weight-loss injection Wegovy and diabetes drug Ozempic, both known chemically as semaglutide, were until recently in shortage in the United States. When asked to elaborate ...

Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide By Robin Foster HealthDay Reporter THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and ...

While semaglutide remains on the shortage list, Novo Nordisk noted last week that the last remaining dose in short supply -- the lowest dose of Wegovy -- is now listed as available, CNN reported.

(MENAFN- IANS) London, Nov 7 (IANS) Danish pharma giant Novo Nordisk has said it is aware of at least 10 deaths and 100 hospitalisations linked to compounded versions of semaglutide -- the active ...